Insider Transaction Report for Corcept Therapeutics Inc.

William Guyer, Chief Development Officer of Corcept Therapeutics Inc., reported a series of transactions on April 7, 2026. Guyer acquired 20,000 shares of Common Stock via the exercise of a stock option at a price of $0.00 per share, increasing his post-transaction holdings to 190,000 shares. Concurrently, he disposed of 20,000 shares of Common Stock at a weighted average price of $40.97 per share, with actual sale prices ranging from $40.85 to $41.30. This sale was executed under a 10b5-1 plan. Following these transactions, his post-transaction holdings of Common Stock amount to 2,231 shares. The report also notes that 224 and 498 shares underlying unvested restricted stock awards granted on December 1, 2025, and March 2, 2026, respectively, are included in his holdings, with full vesting contingent on certain requirements being met.